Institute of Medical Microbiology and Hospital Epidemiology, Hannover Medical School, Hannover, Germany.
J Hosp Infect. 2010 Dec;76(4):300-3. doi: 10.1016/j.jhin.2010.07.007. Epub 2010 Oct 15.
Nosocomial infections with meticillin-resistant Staphylococcus aureus (MRSA) lead to increased health and economic costs. The purpose of this study was to determine costs for nosocomial MRSA pneumonia compared with meticillin-susceptible S. aureus (MSSA) pneumonia. A case-control study was conducted with patients who acquired nosocomial pneumonia with either MRSA or MSSA between January 2005 and December 2007. Patients were matched for age, severity of underlying disease, stay on intensive care units and non-intensive care units, admission and discharge within the same year, and in-hospital stay at least as long as that of cases before MRSA pneumonia. Our analysis includes 82 patients (41 cases, 41 controls). The overall costs for patients with nosocomial MRSA pneumonia were significantly higher than for patients with MSSA pneumonia (€60,684 vs €38,731; P=0.01). The attributable costs for MRSA pneumonia per patient were €17,282 (P<0.001). The financial loss was higher for patients with MRSA pneumonia than for patients with MSSA pneumonia (€11,704 vs €2,662; P=0.002). More cases died than controls while in the hospital (13 vs 1 death, P<0.001). Hospital personnel should be aware of the attributable costs of MRSA pneumonia, and should implement control measures to prevent MRSA transmission.
耐甲氧西林金黄色葡萄球菌（MRSA）引起的医院感染会导致健康和经济成本增加。本研究的目的是确定医院获得性耐甲氧西林金黄色葡萄球菌肺炎（MRSA）与甲氧西林敏感金黄色葡萄球菌（MSSA）肺炎相比的成本。一项病例对照研究纳入了 2005 年 1 月至 2007 年 12 月期间发生医院获得性肺炎的患者，这些患者为 MRSA 或 MSSA 感染。将患者按照年龄、基础疾病严重程度、入住重症监护病房和非重症监护病房时间、入院和出院时间（均在同一年内）、住院时间（至少与 MRSA 肺炎前的病例一样长）进行匹配。我们的分析包括 82 名患者（41 例病例，41 例对照）。MRSA 肺炎患者的总费用明显高于 MSSA 肺炎患者（€60684 比 €38731；P=0.01）。MRSA 肺炎患者的归因费用为每位患者 €17282（P<0.001）。与 MSSA 肺炎患者相比，MRSA 肺炎患者的经济损失更高（€11704 比 €2662；P=0.002）。住院期间发生更多的病例死亡（13 例比 1 例死亡，P<0.001）。医院人员应意识到 MRSA 肺炎的归因成本，并应实施控制措施以预防 MRSA 传播。
